Rheumatism is a chronic self-immunised disease with serious consequences for the quality of life of patients. The emergence of biological agents has brought new breakthroughs in the treatment of rheumatism arthritis. However, patients and their families are often concerned about how long the effects of biological agents in treating rheumatism can last.
Biological agents are single cloned antibodies or integrated proteins produced through genetic engineering, capable of specific target effects on cytogens or cytological surface molecules that are closely related to the rheumatological arthritis mechanism, thus blocking critical elements of inflammatory response. Biological agents are highly effective and effective in comparison with traditional rheumatist drugs. During the initial phase of treatment, many patients have been able to notice a significant reduction in joint pain, swelling, shorter morning rigidities and improved joint functioning within weeks of the use of biological agents.
However, the efficacy of biological agents in treating rheumatism is not constant, but is influenced by a combination of factors. First is the individual difference of the patient. The immune systems of different patients differ in their response to biological agents, with some patients likely to be highly sensitive to biological agents and to be able to sustain treatment for longer periods; others may be relatively weak and have a shorter duration. In general, the efficacy of biological agents may last longer for young, better-healthed patients with relatively single immune responses.
Secondly, the severity and extent of the disease also play a key role. The use of biological agents in early, light-suffering cases of rheumatism begins when the disease has not caused serious damage to the joints and other organs of the body, often with better and longer-lasting treatment. On the contrary, for those with long-term pathologies, which already have significant deformities and functional impairments, and are burdened with multiple systems, biological agents, while also able to alleviate symptoms to some extent, may have a significant reduction in the length of their treatment.
Moreover, the dependence of treatment is an important human factor in determining the duration of the efficacy of biological agents. Biological agents usually require long-term use, and if a patient does not strictly comply with the medical instructions to use the substance on time and in sufficient quantities, reduce its own or stop the drug, it can easily lead to a recurrence of the disease and make the treatment of biological agents unsustainable. In addition, during the use of biological agents, the timely adjustment of the treatment programme to the patient ‘ s condition, if he/she is able to cooperate actively with the doctor for regular review, also helps to extend the duration of the treatment.
From clinical research and extensive treatment practices, some patients are able to manage their condition better after the continued use of biological agents 1-2 years, even to reduce or increase the interval between medications, under the guidance of a doctor, while maintaining stability. However, there are also cases of patients who may experience reduced therapeutic efficacy or a recurrence of disease after months of use.
Overall, the effects of biological agents for the treatment of rheumatism-like arthritis vary over time and are influenced by the interplay of multiple factors. In the course of treatment with biological agents, patients should work closely with doctors to maintain good compliance with treatment and to improve the quality of life by extending the efficacy of biological agents through integrated management.
